It has been reported that serum FGF21 and hepatic mRNA expression levels in patients with NAFLD are significantly higher than those in control subjects, which correlates with a substantial increase in hepatic triglyceride levels [14–16]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.